However, people in the study will continue to be followed and evaluated. The chance of cancer coming back was lowered by 50% for people who received KADCYLA compared to people who received HerceptinĪt this time of this data review, it was too early in the study to determine if people lived longer with KADCYLA.Eighty-eight percent of the 743 people who received KADCYLA were still cancer free, compared to 77% of the 743 people who received Herceptin.Three years after people started the study: This image shows what happened three years after people started the study. One of the goals of neoadjuvant treatment is to help reduce or get rid of cancer cells before surgery.Īdjuvant treatment is given with the intent to kill any cancer cells left behind after surgery. This image provides information about neoadjuvant and adjuvant treatment. KADCYLA is not approved for this use, but you may receive other treatment options. If NO cancer cells are present in the tissue removed, you do not have residual disease.If SOME cancer cells are present in the tissue removed (known as residual disease), you may start on KADCYLA.This image shows what your treatment plan may look like. This image shows lymph nodes to which breast cancer can spread, such as those around or near the collarbone, in the armpits, and near the breastbone. This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |